FDA awards breakthrough status to gene therapy treatment GTX-102
In a significant step forward for the treatment of Angelman syndrome, the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to GTX-102, a gene therapy developed by Ultragenyx Pharmaceutical.
GTX-102 is a promising treatment that could offer hope to families affected by this rare neurodevelopmental disorder. The condition is caused by a missing or mutated maternal copy of the UBE3A gene, leading to a range of symptoms such as intellectual disabilities, motor challenges, and distinct physical characteristics.
The Phase 3 Aspire study, being conducted at sites around the world, is now rapidly enrolling approximately 120 children aged 4 to 17 who lack the maternal UBE3A gene. The study's primary goal is to assess changes in cognitive function as measured with the Bayley-4 Cognition Raw Score.
Participants will receive either GTX-102 or a placebo. Treatment will start with low doses administered every four weeks, followed by a gradual increase in dosage and a longer interval between injections.
The therapy consists of a short strand of genetic material injected into the spinal canal. GTX-102 works by blocking a molecule involved in the genetic regulation of UBE3A, thereby reactivating the normally silent paternal gene.
The decision to grant breakthrough designation was supported by the clinical trial results, which demonstrated clinically meaningful results with GTX-102. No serious side effects related to GTX-102 were reported in the Phase 1/2 trial. Most participants experienced clinically meaningful improvements in areas such as cognition, communication, motor function, sleep, and behavior.
Researchers in the Phase 3 Aspire study will also look at metrics of communication, motor function, and other behaviors, as well as any side effects.
Ultragenyx is not resting on its laurels. The company is planning another trial of GTX-102, called Aurora, in the second half of this year. The Aurora trial will involve participants with a greater range of ages and genetic variants of UBE3A.
The Phase 3 Aspire study will last for 48 weeks, followed by an open-label extension of the same duration.
Ultragenyx Pharmaceutical is currently recruiting participants for its Phase 3 Aspire trial, being conducted at sites around the world, to further evaluate the treatment's effectiveness. For more information about the study or to enquire about participation, interested parties are encouraged to contact Ultragenyx.
With the FDA's breakthrough therapy designation, GTX-102 moves one step closer to becoming a reality for those affected by Angelman syndrome. The potential for this gene therapy to improve the lives of those with this condition is truly exciting.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Tobacco industry's suggested changes on a legislative modification are disregarded by health journalists
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
